SCRIP -- Pharmaxis’ first attempt at getting its cystic fibrosis therapy Bronchitol (mannitol) included in Australia’s reimbursement scheme has been unsuccessful, although the company remains confident it will be eventually be covered. The inhaled dry powder product was considered at the March meeting.
